Add time:07/21/2019 Source:sciencedirect.com
ObjectiveDeterioration in ventricular function is often observed in patients treated with anthracyclines for cancer. There is a paucity of evidence on interventions that might provide cardio-protection. We investigated whether prophylactic use of Carvedilol (cas 72956-09-3) can prevent doxorubicin-induced cardiotoxicity and whether any observed effect is dose related.
We also recommend Trading Suppliers and Manufacturers of Carvedilol (cas 72956-09-3). Pls Click Website Link as below: cas 72956-09-3 suppliers
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View